Sanjeev Gill

1.8k total citations
25 papers, 503 citations indexed

About

Sanjeev Gill is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sanjeev Gill has authored 25 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Sanjeev Gill's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Sanjeev Gill is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Sanjeev Gill collaborates with scholars based in Australia, United States and South Korea. Sanjeev Gill's co-authors include Peter Bergin, Catriona McLean, Rebecca Tay, Elizabeth F. Blackley, Andrew Haydon, Timothy Price, Harri A. Järveläinen, Andrew Dean, Razi Ghori and Corinne Maurice‐Dror and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Sanjeev Gill

24 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sanjeev Gill Australia	14	354	118	116	87	83	25	503
Geoff Chong Australia	9	274 0.8×	117 1.0×	105 0.9×	64 0.7×	111 1.3×	25	414
Thilo Sprenger Germany	16	440 1.2×	148 1.3×	274 2.4×	135 1.6×	52 0.6×	40	634
Giacomo Bregni Italy	12	291 0.8×	141 1.2×	97 0.8×	110 1.3×	62 0.7×	43	443
Shotaro Kato Japan	5	292 0.8×	136 1.2×	61 0.5×	51 0.6×	31 0.4×	14	418
Virginia Arrazubi Spain	12	372 1.1×	235 2.0×	155 1.3×	136 1.6×	49 0.6×	48	641
Elisabetta Fenocchio Italy	12	242 0.7×	87 0.7×	73 0.6×	53 0.6×	83 1.0×	29	337
Aurélie Ferru France	11	250 0.7×	82 0.7×	39 0.3×	93 1.1×	84 1.0×	30	439
Jin Gu China	11	172 0.5×	85 0.7×	96 0.8×	89 1.0×	31 0.4×	36	412
Ulla Lau‐Werner Germany	10	341 1.0×	126 1.1×	118 1.0×	86 1.0×	132 1.6×	13	463
Gregory Pennock United States	8	384 1.1×	132 1.1×	74 0.6×	113 1.3×	48 0.6×	22	527

Countries citing papers authored by Sanjeev Gill

Since Specialization

Citations

This map shows the geographic impact of Sanjeev Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanjeev Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanjeev Gill more than expected).

Fields of papers citing papers by Sanjeev Gill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanjeev Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanjeev Gill. The network helps show where Sanjeev Gill may publish in the future.

Co-authorship network of co-authors of Sanjeev Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Sanjeev Gill. A scholar is included among the top collaborators of Sanjeev Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanjeev Gill. Sanjeev Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rha, Sun Young, Eduardo Castañón, Sanjeev Gill, et al.. (2025). Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort. Cancer. 131(16). e70015–e70015. 1 indexed citations

Michael, Michael, Rachel Wong, Sanjeev Gill, et al.. (2023). The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.. Journal of Clinical Oncology. 41(16_suppl). 3616–3616. 1 indexed citations

Dean, Andrew, et al.. (2022). Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. The Lancet. Gastroenterology & hepatology. 7(10). 943–951. 48 indexed citations

Chung, Hyun Cheol, Zarnie Lwin, Carlos Gomez‐Roca, et al.. (2021). LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.. Journal of Clinical Oncology. 39(15_suppl). 4030–4030. 4 indexed citations

Villanueva-Rivera, Luis J., Zarnie Lwin, Hyun Cheol Chung, et al.. (2021). Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.. Journal of Clinical Oncology. 39(3_suppl). 321–321. 49 indexed citations

Gomez‐Roca, Carlos, Eduardo Yáñez, Seock‐Ah Im, et al.. (2021). LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.. Journal of Clinical Oncology. 39(3_suppl). 94–94. 53 indexed citations

Dean, Andrew, et al.. (2020). 1528P Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. Annals of Oncology. 31. S941–S941. 11 indexed citations

Michael, Michael, Rachel Wong, Sanjeev Gill, et al.. (2019). Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.. Journal of Clinical Oncology. 37(15_suppl). TPS3622–TPS3622. 4 indexed citations

Martin, Andrew, Emma Gibbs, Katrin Marie Sjoquist, et al.. (2017). Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer. 21(3). 473–480. 18 indexed citations

10.

Tay, Rebecca, Elizabeth F. Blackley, Catriona McLean, et al.. (2017). Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. British Journal of Cancer. 117(7). 921–924. 84 indexed citations

11.

Herbertson, Rebecca, Niall C. Tebbutt, Fook-Thean Lee, et al.. (2014). Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of ¹³¹I-huA33 with Concurrent Capecitabine. Journal of Nuclear Medicine. 55(4). 534–539. 24 indexed citations

12.

Sloan, Jeffrey A., M. R. Mahoney, Daniel J. Sargent, et al.. (2011). Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.. Journal of Clinical Oncology. 29(15_suppl). 6122–6122. 16 indexed citations

13.

Huang, Jin, Daniel J. Sargent, M. R. Mahoney, et al.. (2011). Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147.. Journal of Clinical Oncology. 29(15_suppl). 3522–3522. 1 indexed citations

14.

Kumar, Rajiv, et al.. (2011). An Impact of Cross Over Operator on the Performance of Genetic Algorithm Under Operating System Process Scheduling Problem. 704–708. 16 indexed citations

15.

Goldberg, Richard M., Daniel J. Sargent, S. N. Thibodeau, et al.. (2010). Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147.. Journal of Clinical Oncology. 28(15_suppl). 3508–3508. 36 indexed citations

16.

Toh, Han Chong, Brian I. Carr, Sanjeev Gill, et al.. (2010). Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 28(15_suppl). 4038–4038. 16 indexed citations

17.

Gill, Sanjeev, Walter Cosolo, Rebecca Herbertson, Salvatore U. Berlangieri, & Andrew M. Scott. (2009). Medullary carcinoma of the thyroid in a patient with colon cancer and a rising carcinoembryonic antigen level. Internal Medicine Journal. 39(4). 264–265.

18.

Herbertson, Rebecca, Niall C. Tebbutt, Sanjeev Gill, et al.. (2007). Targeted chemoradiation for metastatic colorectal cancer: A phase I trial of oral capecitabine combined with ¹³¹I- huA33. Journal of Clinical Oncology. 25(18_suppl). 4078–4078. 1 indexed citations

19.

Scott, Andrew M., Niall C. Tebbutt, Fook-Thean Lee, et al.. (2007). A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. Clinical Cancer Research. 13(11). 3286–3292. 55 indexed citations

20.

Scott, Andrew M., Sanjeev Gill, Z. Liu, et al.. (2006). A phase I single dose escalation trial of ch806 in patients with advanced tumors expressing the 806 antigen. Journal of Clinical Oncology. 24(18_suppl). 13028–13028. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact